<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Diagnostic criteria of subtypes (variant forms) of systemic mastocytosis (SM)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Diagnostic criteria of subtypes (variant forms) of systemic mastocytosis (SM)</h1>
<div class="graphic"><div class="figure"><div class="ttl">Diagnostic criteria of subtypes (variant forms) of systemic mastocytosis (SM)</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="25%"></colgroup> <tbody> <tr> <td class="subtitle1_left" colspan="4">Indolent and smoldering systemic mastocytosis</td> </tr> <tr> <td class="indent1" colspan="4"><strong>Indolent systemic mastocytosis (ISM)</strong> <ul class="decimal_heading"> <li>SM diagnostic criteria; no "C" findings </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1" colspan="4"><strong>Smoldering systemic mastocytosis (SSM)</strong> <ul class="decimal_heading"> <li>SM diagnostic criteria plus two or more "B" findings; no "C" findings </li> </ul> </td> </tr> <tr> <td class="subtitle1_left" colspan="4">Advanced systemic mastocytosis</td> </tr> <tr> <td class="indent1" colspan="4"><strong>Aggressive systemic mastocytosis (ASM)</strong> <ul class="decimal_heading"> <li>SM diagnostic criteria plus "C" findings; no features of mast cell leukemia </li> </ul> </td> </tr> <tr> <td class="indent1" colspan="4"><strong>Mast cell leukemia (MCL)</strong> <ul class="decimal_heading"> <li>SM diagnostic criteria plus features of MCL </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1" colspan="4"><strong>Systemic mastocytosis with an associated hematologic neoplasm (SM-AHN)</strong> <ul class="decimal_heading"> <li>SM diagnostic criteria plus clonal hematologic nonmast cell lineage disorder (eg, MDS, MPN, AML, lymphoma, other) </li> </ul> </td> </tr> <tr class="divider_top divider_bottom"> <td class="subtitle1">SM diagnostic criteria:</td> <td class="subtitle1">"B" findings:</td> <td class="subtitle1">"C" findings:</td> <td class="subtitle1">Features of MCL:</td> </tr> <tr> <td> <p>Major criterion plus one minor criterion OR three minor criteria.</p> <strong>Major criterion:</strong> <ol> <li>Multifocal, dense infiltrates of mast cells (≥15 mast cells in aggregates) detected in sections of bone marrow and/or other extracutaneous organ(s). </li> </ol> <strong>Minor criterion:</strong> <ol> <li>In biopsy sections of bone marrow or other extracutaneous organs, &gt;25% of the mast cells in the infiltrate are spindle-shaped or have atypical morphology, or of all mast cells in bone marrow aspirate smears, &gt;25% are immature or atypical. </li> <li>Detection of an activating point mutation at codon 816 of KIT in bone marrow, blood, or another extracutaneous organ. </li> <li>Mast cells in bone marrow, blood, or other extracutaneous organs express CD25, with or without CD2, in addition to normal mast cell markers. </li> <li>Serum total tryptase persistently exceeds 20 ng/mL (unless there is an associated clonal myeloid disorder, in which case this parameter is not valid). </li> </ol> </td> <td> <ol class="numbers_to_nine"> <li>Bone marrow biopsy showing &gt;30% infiltration by mast cells (focal, dense aggregates) and/or serum total tryptase level &gt;200 mg/mL. </li> <li>Signs of dysplasia or myeloproliferation in nonmast cell lineage(s) but insufficient criteria for definitive diagnosis of a hematopoietic neoplasm (SM-AHN) with normal or only slightly abnormal blood counts. </li> <li>Hepatomegaly without impairment of liver function, and/or palpable splenomegaly without hypersplenism, and/or lymphadenopathy on palpation or imaging. </li> </ol> </td> <td> <ol class="numbers_to_nine"> <li>Bone marrow dysfunction manifested by one or more cytopenia (ANC &lt;1 × 10<sup>9</sup>/L, Hb &lt;10 g/dL, or platelets &lt;100 × 10<sup>9</sup>/L) but no obvious nonmast cell hematopoietic malignancy. </li> <li>Palpable hepatomegaly with impairment of liver function, ascites, and/or portal hypertension. </li> <li>Skeletal involvement with large osteolytic lesions and/or pathologic fractures. </li> <li>Palpable splenomegaly with hypersplenism. </li> <li>Malabsorption with weight loss due to gastrointestinal mast cell infiltrates. </li> </ol> </td> <td>Bone marrow biopsy shows a diffuse infiltration, usually compact, by atypical, immature mast cells. Bone marrow aspirate smears show ≥20% mast cells.</td> </tr> </tbody></table></div><div class="graphic_lgnd">Solid mast cell tumors (mast cell sarcoma and extracutaneous mastocytoma) are not forms of SM.</div><div class="graphic_footnotes">MDS: myelodysplastic syndrome; MPN: myeloproliferative neoplasm; AML: acute myelogenous leukemia; KIT: the receptor for stem cell factor; ANC: absolute neutrophil count.</div><div class="graphic_reference">Modified with permission from: Horny HP, Metcalfe DD, Bennet JM, et al. Mastocytosis. In: WHO classification of tumours of haematopoietic and lymphoid tissues, 4th ed, Swerdlow SH, Campo E, Harris NL, et al (Eds), IARC: Lyon, 2008. Copyright © 2008.<br/>Additional data from: 

<ol>
<li>Arber DA, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127:2391.</li></ol></div><div id="graphicVersion">Graphic 82828 Version 25.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
